Antimicrobial activity of the new macrolide flurithromycin against Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes, Branhamella catarrhalis and Staphylococcus aureus.
Nord
C E
CE
Department of Microbiology, Huddinge University Hospital, Karolinska Institute and National Bacteriological Laboratory, Stockholm, Sweden.
Lindmark
A
A
Persson
I
I
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004917:Erythromycin / Q000031:analogs & derivatives / Q000494:pharmacology; D006193:Haemophilus influenzae / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D008826:Microbial Sensitivity Tests; D001936:Moraxella catarrhalis / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D012141:Respiratory Tract Infections / Q000382:microbiology*; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development / Q000302:isolation & purification; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000254:growth & development; D013297:Streptococcus pyogenes / Q000187:drug effects* / Q000254:growth & development
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; C045925:flurithromycin; D004917:Erythromycin